Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App Go offline with the Player FM app!
Matt Deseno is the founder of multiple award winning marketing businesses ranging from a attraction marketing to AI appointment setting to customer user experience. When he’s not working on the businesses he teaches marketing at Pepperdine University and he also teaches other marketing agency owners how they created a software company to triple the profitability for the agency. Our Sponsors: * Check out Kinsta: https://kinsta.com * Check out Mint Mobile: https://mintmobile.com/tmf * Check out Moorings: https://moorings.com * Check out Trust & Will: https://trustandwill.com/TRAVIS * Check out Warby Parker: https://warbyparker.com/travis Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy…
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Host: Sara M. Tolaney, MD, MPH This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. FDA Approval January 2025: On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients with HR+, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who have progressed on one or more endocrine therapies in the metastatic setting. On January 17, 2025, datopotamab deruxtecan (Dato-DXd) was approved by the FDA for patients with HR+/HER2- unresectable or metastatic breast cancer who have received prior endocrine therapy and chemotherapy for unresectable or metastatic disease.…
Host: Helena Yu, MD The treatment of EGFR- mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR- mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.…
Host: Matthew S. Davids, MD, MMSc Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL. In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can ……
Host: Joshua E. Reuss, MD Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC. In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are ……
Host: Matthew Lunning, DO, FACP In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management. In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease. This web-based, on-demand activity highlights key clinical trial evidence for bispecific antibodies targeting CD20 and CD3, and how to contextualize the rationale for and clinical utility of integrating CD20 X CD3 bispecific antibodies into community-based clinical practice. Expert faculty offer insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate ……
Host: Sara M. Tolaney, MD, MPH The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine therapy. In this educational activity, expert faculty review a clinical case series highlighting the application of CDK4/6 inhibitors in HR+/HER2− eBC, including identification of patients at high risk of recurrence/progression, selection of adjuvant therapy based on the latest clinical evidence and patient-specific factors, and management of treatment-related adverse events. Approaches to recognizing and addressing racial/ethnic health disparities among minority patients will also be discussed, empowering clinicians to make informed decisions that align with achieving health equity.…
Guest: Kathleen Moore, MD, MS, FASCO The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life. In this educational activity, expert faculty will review potential treatment-related complications that may occur with PARP inhibitor-based therapy. These ……
Guest: Kathleen Moore, MD, MS, FASCO The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life. In this educational activity, expert faculty will review the role of genetic testing in identifying patients likely to benefit ……
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.